Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 1372

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 10
Chunk 1372
---
 the “2019 Plan”) which amended and restated prior plans. Under the 2019 Plan, we are authorized to grant options, restricted shares and restricted share units (“RSUs”) to any of our officers, directors, employees, and consultants and those of our subsidiaries and other designated affiliates. The number of shares available for issuance under the 2019 Plan is 2,367,737. The purpose of the 2019 Plan is to advance the interests of the Company by encouraging equity participation through the acquisition of common shares of the Company. The 2019 Plan is to be administered by the Compensation Committee of our Board, except to the extent (and subject to the limitations set forth in the 2019 Plan) the Board elects to administer the 2019 Plan, in which case the 2019 Plan shall be administered by only those members of the Board who are “independent” members of the Board. The administrator of the 2019 Plan has the power to, among other things:

			●

			allot common shares for issuance in connection with the exercise of options;

			●

			grant options, restricted shares or restricted share units;

			●

			amend, suspend, terminate or discontinue the plan; and

			●

			delegate all or a portion of its administrative powers as it may determine to one or more committees.

Options to purchase 378,039 common shares at prices ranging from C$15.12 and $4.10 to $52.08 are outstanding at September 30, 2025. RSUs eligible for conversion to 333,319 common shares are outstanding at September 30, 2025.

During the year ended September 30, 2025, we did not grant any stock options under the 2019 Plan. During the year ended September 30, 2024, we granted 500 employee options to purchase common shares at an exercise price of $4.10. During the year ended September 30, 2025, we granted 1,227,807 RSUs with varying vesting schedules—certain awards vested immediately upon grant, while others vest in monthly installments over 12 to 36 months. Outstanding RSUs may be converted into common shares by the holder any time after vesting and before the stated expiry. During the year ended September 30, 2024, we granted 30,159 RSUs, which vested immediately upon grant and were issued in lieu of cash